环丙沙星和莫西沙星对巴西诺卡菌的体外抗菌活性及在BALB/c小鼠放线菌瘤实验模型中的疗效
Efficacy of ciprofloxacin and moxifloxacin against Nocardia brasiliensis in vitro and in an experimental model of actinomycetoma in BALB/c mice.
作者信息
Chacon-Moreno Brenda Edith, Welsh Oliverio, Cavazos-Rocha Norma, de la Luz Salazar-Cavazos Maria, Garza-Lozano Hector Gerardo, Said-Fernandez Salvador, Ocampo-Candiani Jorge, Vera-Cabrera Lucio
机构信息
Servicio de Dermatología, Hospital Universitario José E. González, Monterrey, NL, Mexico.
出版信息
Antimicrob Agents Chemother. 2009 Jan;53(1):295-7. doi: 10.1128/AAC.01023-08. Epub 2008 Oct 13.
Abstract
The efficacy of ciprofloxacin and moxifloxacin against Nocardia brasiliensis was evaluated by applying 25 mg of each drug/kg subcutaneously every 8 h in BALB/c mice infected with N. brasiliensis. A statistically significant difference was observed only with moxifloxacin. A moxifloxacin-trimethoprim-sulfamethoxazole combination was as active as when each compound was used alone.
摘要
通过对感染巴西奴卡菌的BALB/c小鼠每8小时皮下注射25毫克/千克的环丙沙星和莫西沙星，评估了这两种药物对巴西奴卡菌的疗效。仅观察到莫西沙星有统计学上的显著差异。莫西沙星-甲氧苄啶-磺胺甲恶唑联合用药与单独使用每种化合物时的活性相同。
相似文献
1
Efficacy of ciprofloxacin and moxifloxacin against Nocardia brasiliensis in vitro and in an experimental model of actinomycetoma in BALB/c mice.环丙沙星和莫西沙星对巴西诺卡菌的体外抗菌活性及在BALB/c小鼠放线菌瘤实验模型中的疗效
Antimicrob Agents Chemother. 2009 Jan;53(1):295-7. doi: 10.1128/AAC.01023-08. Epub 2008 Oct 13.
2
In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice.氟喹诺酮类药物对小鼠全身性兔热病感染的体内疗效。
J Antimicrob Chemother. 2005 Dec;56(6):1069-73. doi: 10.1093/jac/dki359. Epub 2005 Oct 13.
3
Construction of a Nocardia brasiliensis fluorescent plasmid to study Actinomycetoma pathogenicity.构建巴西诺卡氏菌荧光质粒细胞以研究放线菌病的致病性。
Plasmid. 2011 Jan;65(1):25-31. doi: 10.1016/j.plasmid.2010.09.005. Epub 2010 Sep 25.
4
In Vivo Activity of the Benzothiazinones PBTZ169 and BTZ043 against Nocardia brasiliensis.苯并噻嗪酮类化合物PBTZ169和BTZ043对巴西诺卡菌的体内活性
PLoS Negl Trop Dis. 2015 Oct 16;9(10):e0004022. doi: 10.1371/journal.pntd.0004022. eCollection 2015.
5
Evaluation of the Combined Therapy of DA-7218, a New Oxazolidinone, and Trimethoprim/ Sulfamethoxazole in the Treatment of Experimental Actinomycetoma by Nocardia brasiliensis.新型恶唑烷酮DA-7218与甲氧苄啶/磺胺甲恶唑联合治疗巴西诺卡菌所致实验性放线菌瘤的疗效评估。
Curr Drug Deliv. 2010 Jul;7(3):225-9. doi: 10.2174/156720110791560946.
6
Efficacy of DA-7218, a new oxazolidinone prodrug, in the treatment of experimental actinomycetoma produced by Nocardia brasiliensis.新型恶唑烷酮前药DA-7218治疗巴西诺卡菌所致实验性放线菌病的疗效
Molecules. 2008 Jan 11;13(1):31-40. doi: 10.3390/molecules13010031.
7
Systemic increased immune response to Nocardia brasiliensis co-exists with local immunosuppressive microenvironment.系统性增强的对巴西诺卡氏菌的免疫反应与局部免疫抑制微环境共存。
Antonie Van Leeuwenhoek. 2012 Oct;102(3):473-80. doi: 10.1007/s10482-012-9779-y. Epub 2012 Jul 24.
8
Inducible nitric oxide synthase blockade with aminoguanidine, protects mice infected with Nocardia brasiliensis from actinomycetoma development.氨基胍抑制诱导型一氧化氮合酶，可保护感染巴西奴卡菌的小鼠不发生放线菌病。
PLoS Negl Trop Dis. 2020 Oct 22;14(10):e0008775. doi: 10.1371/journal.pntd.0008775. eCollection 2020 Oct.
9
Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis.墨西哥布鲁氏菌分离株对莫西沙星、环丙沙星及其他用于治疗人类布鲁氏菌病的抗菌药物的敏感性。
Scand J Infect Dis. 2004;36(9):636-8. doi: 10.1080/00365540410020767.
10
Immunomodulatory effect of diethylcarbamazine in mice infected with Nocardia brasiliensis.乙胺嗪对巴西诺卡菌感染小鼠的免疫调节作用
Int Immunopharmacol. 2014 Nov;23(1):113-20. doi: 10.1016/j.intimp.2014.08.004. Epub 2014 Aug 18.
引用本文的文献
1
Mycetoma medical therapy.足菌肿的医学治疗。
PLoS Negl Trop Dis. 2014 Oct 16;8(10):e3218. doi: 10.1371/journal.pntd.0003218. eCollection 2014 Oct.
2
Global burden of human mycetoma: a systematic review and meta-analysis.人类足菌肿的全球负担：一项系统评价和荟萃分析。
PLoS Negl Trop Dis. 2013 Nov 7;7(11):e2550. doi: 10.1371/journal.pntd.0002550. eCollection 2013 Nov.
3
Nocardia brasiliensis cell wall lipids modulate macrophage and dendritic responses that favor development of experimental actinomycetoma in BALB/c mice.巴西诺卡氏菌细胞壁脂质调节巨噬细胞和树突状细胞的反应，有利于 BALB/c 小鼠实验性放线菌病的发展。
Infect Immun. 2012 Oct;80(10):3587-601. doi: 10.1128/IAI.00446-12. Epub 2012 Jul 30.
4
In vitro and in vivo intracellular killing effects of tigecycline against clinical nontyphoid Salmonella isolates using ceftriaxone as a comparator.体外和体内使用头孢曲松作为对照比较替加环素对临床非伤寒沙门氏菌分离株的细胞内杀伤作用。
Antimicrob Agents Chemother. 2011 Jun;55(6):2755-9. doi: 10.1128/AAC.01807-10. Epub 2011 Mar 14.
5
In vitro activity of ACH-702, a new isothiazoloquinolone, against Nocardia brasiliensis compared with econazole and the carbapenems imipenem and meropenem alone or in combination with clavulanic acid.新型异噻唑烷酮类药物 ACH-702 对巴西诺卡菌的体外活性研究，与依康唑、碳青霉烯类药物亚胺培南和美罗培南单独或联合克拉维酸比较。
Antimicrob Agents Chemother. 2010 May;54(5):2191-3. doi: 10.1128/AAC.01520-09. Epub 2010 Mar 22.
本文引用的文献
1
In vivo therapeutic effect of gatifloxacin on BALB/c mice infected with Nocardia brasiliensis.加替沙星对感染巴西诺卡菌的BALB/c小鼠的体内治疗效果。
Antimicrob Agents Chemother. 2008 Apr;52(4):1549-50. doi: 10.1128/AAC.00148-08. Epub 2008 Feb 19.
2
Efficacy of DA-7218, a new oxazolidinone prodrug, in the treatment of experimental actinomycetoma produced by Nocardia brasiliensis.新型恶唑烷酮前药DA-7218治疗巴西诺卡菌所致实验性放线菌病的疗效
Molecules. 2008 Jan 11;13(1):31-40. doi: 10.3390/molecules13010031.
3
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.左氧氟沙星、加替沙星和莫西沙星在成年肺结核患者中的群体药代动力学。
Antimicrob Agents Chemother. 2008 Mar;52(3):852-7. doi: 10.1128/AAC.01036-07. Epub 2007 Dec 10.
4
Mycetoma.足菌肿
Clin Dermatol. 2007 Mar-Apr;25(2):195-202. doi: 10.1016/j.clindermatol.2006.05.011.
5
Gatifloxacin and dysglycemia in older adults.加替沙星与老年人血糖异常
N Engl J Med. 2006 Jun 22;354(25):2725-6; author reply 2725-6.
6
Methods for determining spontaneous mutation rates.测定自发突变率的方法。
Methods Enzymol. 2006;409:195-213. doi: 10.1016/S0076-6879(05)09012-9.
7
In vitro activities of new antimicrobials against Nocardia brasiliensis.新型抗菌药物对巴西诺卡菌的体外活性
Antimicrob Agents Chemother. 2004 Feb;48(2):602-4. doi: 10.1128/AAC.48.2.602-604.2004.
8
Treatment of pulmonary nocardiosis in heart-transplant patients: importance of susceptibility studies.心脏移植患者肺部诺卡菌病的治疗：药敏试验的重要性
Clin Transplant. 2001 Dec;15(6):415-20. doi: 10.1034/j.1399-0012.2001.150609.x.
9
Determining mutation rates in bacterial populations.确定细菌群体中的突变率。
Methods. 2000 Jan;20(1):4-17. doi: 10.1006/meth.1999.0901.
10
The clinical use of fluoroquinolones for the treatment of mycobacterial diseases.氟喹诺酮类药物在分枝杆菌疾病治疗中的临床应用。
Clin Infect Dis. 1997 Nov;25(5):1213-21. doi: 10.1086/516116.
Zotero 插件